注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Cellectis SA是一家活躍於基因組工程和基因組外科領域的法國公司。該公司專注於合理基因組工程技術的研究、開發和商業化。該公司開發了一種將大範圍核酸酶與工程靶向脫氧核糖核酸(DNA)基質結合到大範圍核酸酶重組系統(MRS)中的技術,用於基因切除、校正或替換。該公司還提供合理的反向遺傳學和靶向重組工具。Cellectis SA銷售的技術主要用於研究領域、藥物研發項目、農業生物學、生物生產和生物治療領域。Cellectis SA擁有多家子公司。該公司在法國和美國等地開展業務。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Andre Choulika | 58 | 1999 | Co-Founder, CEO & Director |
Jean-Pierre Garnier | 76 | 2020 | Independent Non-Executive Chairman |
Marcela V. Maus | 46 | 2017 | Member of Clinical Advisory Board |
Ghulam J. Mufti | - | - | Member of Clinical Advisory Board |
Dietger Niederwieser | - | 2017 | Member of Clinical Advisory Board |
Ola Landgren | - | 2017 | Member of Clinical Advisory Board |
Kanti Rai | - | 2017 | Member of Clinical Advisory Board |
Catherine Bollard | 54 | 2017 | Member of Clinical Advisory Board |
Stephan A. Grupp | - | 2018 | Member of Clinical Advisory Board |
Cecile Chartier | - | 2023 | Director |
David J. D. Sourdive | 56 | 2000 | Deputy CEO, Executive VP of CMC & Manufacturing and Director |
Rainer J. Boehm | 63 | 2017 | Director |
Pierre Bastid | 69 | 2011 | Director |
Donald A. Bergstrom | 51 | 2021 | Director |
Axel-Sven Malkomes | 56 | 2022 | Director |
Laurent Arthaud | 60 | 2011 | Director |
Marc Dunoyer | 72 | 2023 | Director |
Tyrell Rivers | 51 | 2023 | Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核